Across all risk categories, 19.6% of patients with metastatic disease were administered prophylactic G-CSF in cycle 1, including 48.5% of HR patients, 13.9% of IR + 1 patients, and 11.1% of all other patients (Fig. 1a). This evidence concerns the gene CSF3 and metastatic neoplasm.